Table 4 Movement disorders
From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator | Outcomes | Conclusions from data | AMSTAR-2 rating |
|---|---|---|---|---|---|---|---|---|
Koppel, 2014 [85] | Inception–Nov 2013; 5 | Non-profit | 34 | MS, HD, PD, cervical dystonia, Tourette syndrome, epilepsy | I: All types of cannabinoids C: Placebo | • Spasticity • Central NP • Bladder symptoms • Tremor • Symptomatic HD treatment • Levodopa-induced dyskinesias • Tic severity • Cervical dystonia • Seizure frequency • Discontinuation of medication due to AEs | Reported SBS for all outcomes except discontinuation of medication due to AEs (favors placebo) | L |
Mestre, 2009 [75] | Start search date varies by database to Dec 2007; 4 | Non-profit | 1 | HD | I: Plant-derived cannabinoids C: placebo | • Chorea severity • Functional capacity • HD staging system • Motor function (SCL-90R) • Cognition (SCL-90R) • Psychological distress (SCL-90R) | Only one study included | M |
Chung, 2006 [78] | Searched in Jul 2005; 11 | Non-profit | 1 | PD | I: Plant-based cannabis C: placebo | • Therapeutic effect on L-dopa induced dyskinesia • Unified PD rating scale • QoL • Total AEs | Only one study included | L |
Pringsheim, 2012 [86] | MEDLINE 1950 and EMBASE 1980 to Oct 2010; 2 | Government | 2 | Tic disorders | I: Plant-derived cannabinoids C: Placebo | • Tic frequency and severity • Total AEs | Favors intervention | L |
Curtis, 2009 [57] | Start search date varies by database and runs “to date”; 8 | Government | 2 | Tourette syndrome | I: Plant-derived cannabinoids C: Placebo | • Tic reduction • Tic severity • STSSS • YGTSS • TSSL • Obsessive Compulsive disorder (TSSL) • TS–CGI • Video rating • Total AEs | Favors intervention for tic reduction; reported SBS for total AEs; only one study included for all other outcomes | M |